Claims
- 1. An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3; b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and c) a nucleic acid molecule which encodes a naturally occurring variant of the polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof, under stringent conditions.
- 2. The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.
- 3. A host cell which contains the nucleic acid molecule of claim 1.
- 4. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.
- 5. An isolated polypeptide selected from the group consisting of:
a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3, or a complement thereof; and b) a naturally occurring variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID NO:3, or a complement thereof under stringent conditions.
- 6. An antibody which selectively binds to a polypeptide of claim 5.
- 7. A method for producing a polypeptide selected from the group consisting of:
a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, or a complement thereof under stringent conditions; comprising culturing the host cell of claim 3 under conditions in which the nucleic acid molecule is expressed.
- 8. A method for detecting the presence of a polypeptide of claim 5 in a sample from a subject with a cardiovascular disorder, comprising:
a) contacting the sample with a compound which selectively binds to a polypeptide of claim 5; and b) determining whether the compound binds to the polypeptide in the sample.
- 9. The method of claim 8, wherein the compound which binds to the polypeptide is an antibody.
- 10. A kit comprising a compound of claim 8 and instructions for use.
- 11. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample from a subject with a cardiovascular disorder, comprising the steps of:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
- 12. The method of claim 11, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
- 13. A kit comprising a the nucleic acid probe or primer of claim 11 and instructions for use.
- 14. A method for identifying a compound which binds to a polypeptide of claim 5 comprising the steps of:
a) contacting a polypeptide, or a cell expressing a polypeptide of claim 5 with a test compound; and b) determining whether the polypeptide binds to the test compound.
- 15. A method for modulating the activity of a polypeptide of claim 5 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 5 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
- 16. A method for identifying a compound which modulates the activity of a polypeptide of claim 5, comprising:
a) contacting a polypeptide of claim 5 with a test compound; and b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
- 17. A method of identifying an agent which modulates the expression of a nucleic acid encoding a protein of claim 5, comprising:
a) exposing cells which express the nucleic acid to the agent; and b) determining whether the agent modulates expression of said nucleic acid, thereby identifying an agent which modulates the expression of a nucleic acid encoding the protein.
- 18. A method of assessing whether a subject is afflicted with a cardiovascular disorder, comprising:
a) measuring the level of expression of VELP2 in a subject; and b) comparing the level measured in a) with the level of VELP2 in a normal sample, wherein a higher level of VELP2 expression in the subject sample indicates that the subject has a cardiovascular disorder.
- 19. The method of claim 18, wherein the measurement of expression measures VELP2 mRNA.
- 20. The method of claim 18, wherein the measurement of expression measures VELP2 protein.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S. patent application Ser. No. 10/273,680, filed Oct. 18, 2002, which claims the benefit of U.S. Provisional Application No. 60/329,756, filed Oct. 18, 2001, the contents of both applications are incorporated herein by this reference in their entireties.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60329756 |
Oct 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10273680 |
Oct 2002 |
US |
Child |
10889340 |
Jul 2004 |
US |